# EDGAR Filing Document

**Accession Number:** 0001723464
**File Stem:** 0001723464-26-000008
**Filing Date:** 2026-3
**Character Count:** 4629
**Document Hash:** e18d0bbaf001b9f9dfaaced16596bbb7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001723464-26-000008.hdr.sgml**: 20260306

**ACCESSION NUMBER**: 0001723464-26-000008

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260306

**FILED AS OF DATE**: 20260306

**DATE AS OF CHANGE**: 20260306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOHARVEST SCIENCES INC.
- **CENTRAL INDEX KEY:** 0001723464
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42389
- **FILM NUMBER:** 26731360

**BUSINESS ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6
- **BUSINESS PHONE:** 6046221186

**MAIL ADDRESS:**
- **STREET 1:** 1140 - 625 HOWE STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 2T6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CANNA-V-CELL SCIENCES INC.
- **DATE OF NAME CHANGE:** 20191008

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Midnight Star Ventures Corp.
- **DATE OF NAME CHANGE:** 20171121

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March 2026**

Commission file number: **001-42389**

**BIOHARVEST SCIENCES INC.**

(Exact name of Registrant as specified in its charter)

**Not applicable**

(Translation of Registrant's name into English)

**1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**SUBMITTED HEREWITH**

**Exhibits:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Description** |
| &nbsp;&nbsp;[99.1](bhsc_ex991.htm) | &nbsp;&nbsp;Material Change Report dated March 6, 2026 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**BIOHARVEST SCIENCES INC.** |
|  | &nbsp;&nbsp;(Registrant) |
| &nbsp;&nbsp;Date: March 6, 2026 | &nbsp;&nbsp;*/s/ David Ryan* |
|  | &nbsp;&nbsp;Name: David Ryan |
|  | &nbsp;&nbsp;Title: Vice-President, Investor Relations & Secretary |

---

## Exhibit 99.1

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1.** **Name and Address of Company**

**BIOHARVEST SCIENCES INC.**

Suite 1140 – 625 Howe Street

Vancouver, BC, V6C 2T6

(the "Company" or "BioHarvest")

**Item 2.** **Date of Material Change**

March 3, 2025.

**Item 3.** **News Release**

The news release was issued on March 5, 2026 and disseminated by Newsfile Corp.

**Item 4.** **Summary of Material Change**

The Company announced changes to it's board of directors.

**Item 5.** **Full Description of Material Change**

The Company announced the resignation of David Tsur as a director of the Company. Mr. Tsur served as a director since 2021. The Company also announced the immediate appointment of Prof. Hezi Levy to replace Mr. Tsur on its board of directors.

Prof. Levy joins the Board with decades of leadership experience across Israel's healthcare system. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy. Prof. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel's major hospitals and complex healthcare operations.

**Item 6.** **Reliance on Subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7.** **Omitted Information**

None.

**Item 8.** **Executive Officer**

For further information, please contact:

**David Ryan**

Secretary and VP, Investor Relations

604 622-1187

**Item 9.** **Date of Report**

March 6, 2026.